HeimB1NT34 • BVMF
add
Biontech Se Bdr
Við síðustu lokun
27,84 R$
Dagbil
27,84 R$ - 28,20 R$
Árabil
25,78 R$ - 43,61 R$
Markaðsvirði
22,57 ma. USD
Meðalmagn
920,00
V/H-hlutf.
-
A/V-hlutfall
-
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (EUR) | des. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 907,40 m. | -23,75% |
Rekstrarkostnaður | 907,20 m. | 15,13% |
Nettótekjur | -305,00 m. | -217,53% |
Hagnaðarhlutfall | -33,61 | -254,10% |
Hagnaður á hvern hlut | -0,33 | -130,56% |
EBITDA | -266,95 m. | -195,92% |
Virkt skatthlutfall | -34,12% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (EUR) | des. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 13,74 ma. | -13,28% |
Heildareignir | 21,99 ma. | -2,40% |
Heildarskuldir | 2,76 ma. | -11,36% |
Eigið fé alls | 19,22 ma. | — |
Útistandandi hlutabréf | 239,97 m. | — |
Eiginfjárgengi | 0,36 | — |
Arðsemi eigna | -3,49% | — |
Ávöxtun eigin fjár | -3,96% | — |
Peningaflæði
Breyting á handbæru fé
| (EUR) | des. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | -305,00 m. | -217,53% |
Handbært fé frá rekstri | 309,50 m. | 166,80% |
Reiðufé frá fjárfestingum | -2,73 ma. | -549,25% |
Reiðufé frá fjármögnun | -14,30 m. | -95,89% |
Breyting á handbæru fé | -2,42 ma. | -1.860,74% |
Frjálst peningaflæði | -1,44 ma. | -27,63% |
Um
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Framkvæmdastjóri
Stofnsett
2008
Vefsvæði
Starfsfólk
7.807
